Biotech advancements often face delays due to bureaucracy, hindering the development of necessary therapies. Now is the time for us to overhaul the archaic procedural measures, including the Food and Drug Administration’s (FDA) outdated policies and procedures. If we continue to permit bureaucracy to impede the advancement of science, then people will continue to die waiting for therapeutic advances – and that is unacceptable.
Read Full Article »
